Background: Several antibiotics can be used to treat ventilator-associated pneumonia caused by carbapenem-resistant A. baumannii (CRAB-VAP) including high-dose sulbactam. However, the effectiveness of high-dose sulbactam therapy is not well known. We report our experience with high-dose sulbactam for treatment of CRAB-VAP. 
Introduction
Acinetobacter baumannii (A. baumannii) a non-lactose-fermenting, gram-negative coccobacillus found extensively in nature, has emerged as a major cause of nosocomial infection in critical care settings. [1] This microorganism is characterized by the rapid acquisition of resistance to multiple antibiotics [2] and survives longer in inanimate objects such as ventilator circuits, rubber, steel, and plastic and can colonize anywhere in the intensive care unit (ICU). [3] Due to its ability to survive for an extended period of time on the surfaces of medical equipment and to acquire multiple antibiotic resistance, A. baumannii is a common cause of nosocomial infection, [4] causing a wide range of infections including wound infections, urinary tract infections, meningitis, bacteremia, and ventilator-associated pneumonia (VAP). In VAP, carbapenem-resistant A. baumannii (CRAB) is currently one of the most problematic pathogens because the antimicrobial choices are limited due to the inherent and acquired resistance of the microorganism.
Several trials have evaluated effective antimicrobial
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Materials and Methods

1) Study design
This was a retrospective case series study conducted in the 58-bed adult ICU of a university hospital in Daejeon, The attending physician adjusted the dose based on the patient's body weight and kidney function. In our hospital, cefoperazone-sulbactam was not available and thus was not included in this study.
4) Microbiological methods
Sputum samples were collected by bronchoscopic lavage or endotracheal suction. Microbial identification and susceptibility testing were conducted using the Mi- 
Results
During the study period, 58 CRAB-VAP patients were treated with high-dose sulbactam. Table 1 Among the patients, 17 (29.3%) died within 30 days after CRAB-VAP diagnosis; 15-day mortality was 12.1%. 
Discussion
Several previous studies evaluated the efficacy of high-dose sulbactam for the treatment of CRAB-VAP.
However, because the studies were conducted with small populations, mortality predictors were not assessed. Betrosian et al.
[22] conducted a prospective study comparing the efficacy of ampicillin-sulbactam and colistin for the treatment of CARB-VAP. In their study, 13 patients Values are presented as mean ± SD or n (%). In this study, two forms of sulbactam were used, piper- This study had several limitations. The study was adapted from a single center, and a small number of patients were enrolled. Additionally, the study was conducted retrospectively, so selection bias may have occurred.
Since treatment was administered by several attending physicians from the medical or surgical ICU, the decisions were physician-dependent despite similar clinical situations. Radiologic review was performed by only one physician; thus, the validity of the review cannot be guaranteed.
We conclude that high-dose sulbactam can be effective for the treatment of CRAB-VAP. However, early clinical failure is common and is associated with higher mortality with this treatment. Therefore, we recommend prompt change of antibiotics when clinical deterioration is observed during the early stages of high-dose sulbactam treatment. A larger prospective randomized controlled study is recommended.
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